Vicore Pharma Unveils Promising IPF Treatment Data at ATS Conference

Vicore Pharma Holding AB ( (SE:VICO) ) has provided an update.

Vicore Pharma Holding AB presented new data at the 2025 American Thoracic Society International Conference, highlighting the potential of their drug buloxibutid for treating idiopathic pulmonary fibrosis (IPF). The data from the Phase 2a AIR trial showed significant improvement in lung function among participants and demonstrated buloxibutid’s superior anti-fibrotic activity compared to existing treatments. The ongoing Phase 2b ASPIRE trial is designed with patient-friendly features to enhance participation and retention, while a digital therapeutic, Almee, was shown to improve quality of life in pulmonary fibrosis patients.

More about Vicore Pharma Holding AB

Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on developing a novel class of drugs for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Their lead program, buloxibutid (C21), is an oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the US FDA and is in a global Phase 2b trial.

Average Trading Volume: 364,255

Current Market Cap: SEK1.92B

See more data about VICO stock on TipRanks’ Stock Analysis page.